User profiles for Clifton Bingham

Clifton Bingham

Johns Hopkins University
Verified email at jhmi.edu
Cited by 35740

2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

…, J Funovits, DT Felson, CO Bingham III… - Arthritis & …, 2010 - Wiley Online Library
Objective The 1987 American College of Rheumatology (ACR; formerly, the American
Rheumatism Association) classification criteria for rheumatoid arthritis (RA) have been criticized …

[HTML][HTML] Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis

…, MM Hooper, JD Bradley, CO Bingham III… - … England Journal of …, 2006 - Mass Medical Soc
Background Glucosamine and chondroitin sulfate are used to treat osteoarthritis. The
multicenter, double-blind, placebo- and celecoxib-controlled Glucosamine/chondroitin Arthritis …

Catastrophizing and pain in arthritis, fibromyalgia, and other rheumatic diseases

RR Edwards, CO Bingham III, J Bathon… - Arthritis Care & …, 2006 - Wiley Online Library
Objective Pain is among the most frequently reported, bothersome, and disabling symptoms
described by patients with osteoarthritis, rheumatoid arthritis, fibromyalgia, and other …

[HTML][HTML] Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0

…, MA d'Agostino, PG Conaghan, CO Bingham III… - Journal of clinical …, 2014 - Elsevier
Background Lack of standardization of outcome measures limits the usefulness of clinical
trial evidence to inform health care decisions. This can be addressed by agreeing on a …

Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial

CO Bingham III, RJ Looney, A Deodhar… - … : Official Journal of …, 2010 - Wiley Online Library
Objective To examine immunization responses in patients with rheumatoid arthritis (RA) treated
with rituximab and to investigate the effects of rituximab‐induced CD20+ B cell depletion …

Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial …

CO Bingham III, JC Buckland‐Wright… - … : Official Journal of …, 2006 - Wiley Online Library
Objective Bisphosphonates have slowed the progression of osteoarthritis (OA) in animal
models and have decreased pain in states of high bone turnover. The Knee OA Structural …

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

RF Van Vollenhoven, P Emery, CO Bingham… - Annals of the …, 2013 - ard.bmj.com
Objectives Evaluation of long-term safety of rituximab in rheumatoid arthritis (RA). Methods
Pooled observed case analysis of data from patients with moderate-to-severe, active RA …

The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial

…, MF Finco, DD Dunlop, CO Bingham III… - … : Official Journal of …, 2008 - Wiley Online Library
Objective Osteoarthritis (OA) of the knee causes significant morbidity and current medical
treatment is limited to symptom relief, while therapies able to slow structural damage remain …

Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from …

…, F Wolfe, J Lisse, DE Furst, CO Bingham… - Annals of the …, 2010 - ard.bmj.com
Background Knee osteoarthritis (OA) is a major cause of pain and functional limitation in
older adults, yet longer-term studies of medical treatment of OA are limited. Objective To …

Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab

…, J Naidoo, JR Brahmer, D Le, CO Bingham - Annals of the …, 2017 - ard.bmj.com
Objectives Immune checkpoint inhibitors (ICIs) targeting the cytotoxic T-lymphocyte-associated
protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) pathways have …